Clinical trials: Neuroendocrine Tumor Metastatic
Vitiligo, Skin Melanoma
Defining the Role of the Skin Microbiome in Immune-related Adverse Events
The skin microbiome has been implicated in several cutaneous autoimmune pathologies such as psoriasis and atopic dermatitis. However, its role in vitiligo and vitiligo lesions occuring in patients receiving anti-PD-1 for…
- Trial name
- SKINBIOTA (NCT04734704)
- Testing
- skin swabs at lesional and non-lesional sites, skin swabs on skin
- Where
- France
- Volunteers
- 57 people
- Sponsor
- University Hospital, Bordeaux
Midgut Neuroendocrine Tumors
Exploration of Molecular Biomarkers for Lu-177 DOTATATE Therapy in Midgut Neuroendocrine Tumor
Midgut neuroendocrine tumours present an increasing incidence and poor survival at 5 years with limited therapeutic options for metastatic, non-operable cases.
- Trial name
- GENEBIOLuNET (NCT03667092)
- Testing
- non-drug intervention type
- Where
- France
- Volunteers
- 47 people
- Sponsor
- University Hospital, Toulouse
Neuroendocrine Tumors
Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases
This is a safety study to determine the phase 1 starting dose of [90]Yttrium-DOTATOC when it is administered intravenously for patients with neuroendocrine tumors that have spread to the liver.
- Trial name
- NCT03724409
- Testing
- [90]Y-DOTATOC
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Sandeep Laroia
Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Spine
SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine
This phase I pilot trial studies the side effects of stereotactic radiosurgery and nivolumab in treating patients with newly diagnosed melanoma that has spread to the brain or spine.
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Spine, Stage IV Skin Melanoma
- Trial name
- NCT02716948
- Testing
- Laboratory Biomarker Analysis, Nivolumab, Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Neuroendocrine Tumor
Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors
This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors…
- Trial name
- NCT05724108
- Testing
- Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate
- Where
- 25 sites in United States
- Volunteers
- 94 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Melanoma
Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma
The primary objective of this trial is to compare the survival of patients with metastatic malignant melanoma treated with Taxoprexin Injection to those treated with Dacarbazine.
- Trial name
- NCT00087776
- Testing
- Taxoprexin, Dacarbazine
- Where
- United States
- Volunteers
- 393 people
- Sponsor
- American Regent, Inc.
Unresectable or Metastatic Melanoma
NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
This was a Phase 1, open-label, non-randomized study of the combination of NY-ESO-1 plus ipilimumab in patients with unresectable or metastatic melanoma for whom treatment with ipilimumab was indicated.
- Trial name
- NCT01810016
- Testing
- Ipilimumab, NY-ESO-1 Protein Vaccine, NY-ESO-1 OLP4 Vaccine with Poly-ICLC and Montanide
- Where
- 5 sites in United States, Australia
- Volunteers
- 8 people
- Sponsor
- Ludwig Institute for Cancer Research
Melanoma
Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma
This feasibility study aims to determine if intermittent dosing is deliverable, based on patient and professional willingness to take part in a randomised trial evaluating less rather than the standard durations of treatment.
- Trial name
- INTERIM (NCT03352947)
- Testing
- Dabrafenib, Trametinib
- Where
- United Kingdom
- Volunteers
- 79 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Uveal Melanoma
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
A phase Ib dose-escalation study of the AEB071 and MEK162 combination in adult patients with confirmed metastatic uveal melanoma.
- Trial name
- NCT01801358
- Testing
- AEB071, MEK162
- Where
- 7 sites in United States, France and 4 more
- Volunteers
- 38 people
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
Pheochromocytoma, Metastatic, Pheochromocytoma Malignant
The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment
Metastatic pheochromocytoma / paraganglioma (MPP) are rare while the prognosis was poor. Penpulimab is specifically an immune check-point inhibitor of PD1 and has been approved for the treatment of several malignancies.This phase…
- Conditions
- Pheochromocytoma, Metastatic, Pheochromocytoma Malignant, Paraganglioma, Malignant
- Trial name
- NCT05885399
- Testing
- Penpulimab
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Peking Union Medical College Hospital
Uveal Melanoma
Adjuvant Tebentafusp in High Risk Ocular Melanoma
At least 50% of patients with high-risk primary uveal melanoma will develop a recurrence following treatment of the primary tumour. Observation is currently the standard of care in the non-metastatic setting.
- Trial name
- ATOM (NCT06246149)
- Testing
- Tebentafusp
- Where
- 15 sites in United States, Belgium and 7 more
- Volunteers
- 290 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
This phase II trial studies how well encorafenib and binimetinib work before surgery in treating patients with BRAF V600-mutated stage IIIB-D melanoma that has spread to the lymph nodes.
- Conditions
- Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
- Trial name
- NCT04221438
- Testing
- Binimetinib, Conventional Surgery, Encorafenib
- Where
- 10 sites in United States
- Volunteers
- 3 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Melanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma
Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma
You are being asked to take part in this study because you have advanced melanoma. The goal of this clinical research study is to learn if oral azacitidine (CC-486) and pembrolizumab (MK-3475) can help to control melanoma.
- Trial name
- NCT02816021
- Testing
- Azacitidine, Pembrolizumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs".
- Trial name
- NCT06246916
- Testing
- fianlimab, cemiplimab, relatlimab+nivolumab
- Where
- 113 sites in United States, Canada
- Volunteers
- 560 people
- Sponsor
- Regeneron Pharmaceuticals
Metastatic Melanoma
Sequential Combo Immuno and Target Therapy (SECOMBIT) Study
To evaluate the best sequencing approach with the combination of target agents (LGX818 plus MEK162) and the combination of immunomodulatory antibodies (ipilimumab plus nivolumab) in patients with metastatic melanoma and BRAF V600…
- Trial name
- SECOMBIT (NCT02631447)
- Testing
- LGX818, MEK162, Nivolumab
- Where
- 30 sites in Austria, France and 8 more
- Volunteers
- 251 people
- Sponsor
- Fondazione Melanoma Onlus
Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
The purpose of this study is to learn about the safety and the effects of PF-08046037 alone or with sasanlimab for the treatment of certain advanced or metastatic malignancies.
- Conditions
- Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Trial name
- NCT06974734
- Testing
- PF-08046037, sasanlimab
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 8 people
- Sponsor
- Pfizer
Melanoma
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not worse than nivolumab + relatlimab FDC intravenous (IV) administration in…
- Trial name
- RELATIVITY-127 (NCT05625399)
- Testing
- Nivolumab + Relatlimab, rHuPH20
- Where
- 149 sites in United States, Australia and 17 more
- Volunteers
- 579 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Melanoma
Multicenter Tissue Registry in Melanoma
The prospective multicenter translational study Tissue Registry in Melanoma (ADOREG/TRIM; CA209-578) aimed to validate the Tumor Mutational Burden (TMB) and the PD-L1 expression (PD-L1) from a pre-therapeutically obtained tumor…
- Trial name
- TRIM (NCT05750511)
- Testing
- molecular tissue analysis
- Where
- 14 sites in Germany
- Volunteers
- 1,000 people
- Sponsor
- Dermatologic Cooperative Oncology Group
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines made from a person's white blood cells and melanoma cells may make the body build an immune response and kill tumor cells.
- Trial name
- NCT00003792
- Testing
- MART-1 antigen, filgrastim, flu matrix peptide p58-66
- Where
- United States
- Sponsor
- Baylor Health Care System
Melanoma
PD-L1 PET Imaging in Melanoma Patients
This is a feasibility study for the use of [18F]PD-L1 as a PET tracer that will be conducted in a single center. The study consists of two phases.
- Trial name
- NCT03520634
- Testing
- PD-L1 PET imaging
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- University Medical Center Groningen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.